We are pleased to welcome @eortc.org as BLOODPAC’s newest member. EORTC is an international, nonprofit cancer research organization coordinating clinical and translational studies to help improve patient outcomes worldwide.

#BLOODPAC #CancerResearch

Celebrating the publication of the “Generic Protocols for Analytical Validation of Tumor-Informed ctDNA Assays for MRD: The BLOODPAC MRD AV Working Group Consensus Recommendation” in JCO PO and now advancing tumor-agnostic protocols. Great in-person progress on the next manuscript.

#BLOODPAC #MRD

Expanding our MRD work to focus on clinical utility.
At this workshop, co-chairs and members refined the goals and scope for a potential new working group. Strong engagement and great momentum for this next phase.

#BLOODPAC #MRD #ClinicalUtility

Great Q1 meeting for the Multi-Omics WG at @guardanthealth.bsky.social!

The team refined key lexicon terms and, after strong progress this past year, is now launching two subgroups: Pre-Analytic/Lab and Data/AI. Momentum continues!

#BLOODPAC #MultiOmics

During the BLOODPAC Q1 Day 1 recap, the RDE Working Group shared a new project developing Minimum Technical Data Elements (MTDEs) for saliva and buccal samples. An outstanding group of experts is helping shape and accelerate this effort.
#BLOODPAC

New Standards Introduced for Liquid Biopsy Tests Monitoring Cancer Recurrence The BLOODPAC Consortium has published a new document detailing standards for liquid biopsy tests in JCO Precision Oncology, aiming to enhance cancer care.

New Standards Introduced for Liquid Biopsy Tests Monitoring Cancer Recurrence #USA #Chicago #Liquid_Biopsy #Cancer_Recurrence #BLOODPAC

BLOODPAC Sets New Standards for Liquid Biopsy Tests to Monitor Cancer Recurrence BLOODPAC has published new standards for liquid biopsy tests aimed at monitoring cancer recurrence. This framework enhances test validation and patient care.

BLOODPAC Sets New Standards for Liquid Biopsy Tests to Monitor Cancer Recurrence #USA #Chicago #Liquid_Biopsy #Cancer_Recurrence #BLOODPAC

Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem.

#BLOODPAC #Biofidelity

Huge thanks to all who joined our 4th Annual BLOODPAC New Frontiers Seminar: “New Frontiers in Therapy Selection: Beyond DNA Mutations.” Inspiring talks & discussions on the future of precision oncology! Highlights coming soon! #LiquidBiopsy #TherapySelection #PrecisionOncology #BLOODPAC

👏 Thanks to everyone who joined our Summer Seminar yesterday!

We’re already working to bring you something special this fall:

🎯New Frontiers in Therapy Selection: Beyond DNA Mutations
📅 Nov 5, 2025

Mark your calendars—details coming soon!

#liquidbiopsy #cancerresearch #multimodal #BLOODPAC

Home | Liquid Biopsy for Precision Oncology East Coast The Liquid Biopsy for Precision Oncology East Coast Summit returns, the only forum diving into barriers slowing the adoption of liquid biopsy

Tomorrow! Don’t miss our Executive Director’s presentation at the 4th Liquid Biopsy for Precision Oncology Summit – East Coast in Boston.

Learn more on the event website: lbx-summit-east.com

#LiquidBiopsy #BLOODPAC

📢 The BLOODPAC Dictionary is live! Explore key terms developed by the community to support clarity and collaboration in liquid biopsy.

Check it out → www.bloodpac.org/bloodpac-dic...

#BLOODPAC #LiquidBiopsy #PrecisionMedicine

Our Q1 meeting at Natera showed the power of in-person collaboration.
Kelli, Chair of our Blood Collection WG, put it best:
"We had great discussions on next steps and how to develop a validation plan to bring to the FDA."

Big progress, driven by teamwork. 💥
#LiquidBiopsy #Collaboration #BLOODPAC

LinkedIn This link will take you to a page that’s not on LinkedIn

🚨 Upcoming Webinar Alert! 🚨

Join us on Wednesday, June 18 at 12:00 PM ET for a live conversation on liquid biopsy innovation and expanding patient access to cutting-edge diagnostics.

🔗 Register now: lnkd.in/gwdMS5ZA

#LiquidBiopsy #CancerDiagnostics #BLOODPAC #PrecisionMedicine #Webinar

Don't miss our "Modernizing Performance Statistics for Clinical Validation of Blood-based Cancer Screening Tests" in a few minutes in room S1006!

#BLOODPAC #Statistics #ClinicalValidation #bloodbasedcancerscreening #AACR25

Busy session for the Recommended Data Elements Working Group at BLOODPAC’s Q1 2025 meeting!

They worked on defining use cases for platform data elements and tackled revisions for a peer-reviewed paper they hope will be published soon. Lots of exciting work ahead!

#LiquidBiopsy #BLOODPAC

At BLOODPAC’s Q1 2025 meeting, the MRD Clinical Validation Working Group reviewed use case examples to shape guidelines for clinical validity. Now, they’re preparing a presubmission to the FDA for feedback. Exciting progress!

#MRD #LiquidBiopsy #BLOODPAC

Big progress from the CHIP Working Group at BLOODPAC’s Q1 2025 meeting!

They’re wrapping up a lexicon on CHIP to bring clarity to the field, almost ready for peer review! Exciting work ahead.

#CHIP #LiquidBiopsy #BLOODPAC

Big news from BLOODPAC’s Q1 2025 meeting, the Multi-Omics Working Group is officially launched!

The group set 2-year goals and brainstormed key challenges in the field. Looking forward to seeing how they push multi-omics & liquid biopsy forward!

#MultiOmics #liquidbiopsy #BLOODPAC

Big news! Our MRD Advisory Group’s latest paper has been accepted! This lexicon lays the foundation for standardized liquid biopsy MRD definitions, with a focus on ctDNA detection.
Keep an eye on our socials and website—the publication drops soon!

#MRD #LiquidBiopsy #ctDNA #BLOODPAC